Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland · Delayed Price · Currency is CHF 71.30
+0.30 (0.42%)
Nov 12, 2026, 1:01 PM CET
Basilea Pharmaceutica AG Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Basilea Pharmaceutica AG stock has a consensus rating of "Buy" and an average price target of CHF 99.62. The average 1-year stock price forecast is 39.72% higher than the current stock price, while the lowest is CHF 67.00 (-6.03%) and the highest is CHF 126.10 (+76.86%).
Price Target: CHF 99.62 (+39.72%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Sep 11, 2026.
Analyst Ratings
The average analyst rating for Basilea Pharmaceutica AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains CHF 105.00 → CHF 110.00 | Buy | Maintains | CHF 105.00 → CHF 110.00 | +54.28% | Sep 11, 2026 |
Financial Forecast
Revenue This Year
273.30M
from 232.38M
Increased by 17.61%
Revenue Next Year
294.24M
from 273.30M
Increased by 7.66%
EPS This Year
4.93
from 3.14
Increased by 56.89%
EPS Next Year
5.13
from 4.93
Increased by 4.13%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CHF.